Strategy for prevention of uterine leiomyoma recurrence in combination with adenomiosis after organ-conserving operations in reproductive aged women




uterine leiomyoma in combination with endometriosis, myomectomy, postoperative therapy, long-term surgery results, tumor recurrence


Aim of the study: to reduce the number of relapses and improve the reproductive function of women after surgical removal of uterine leiomyoma (LM).

Materials and methods: the study included 76 women of reproductive age who underwent organ-preserving surgical treatment for LM. Women were divided into two groups depending on the adenomyosis presence. Group I included 35 women with isolated LM, group II included 41 women with LM in combination with adenomyosis. Groups I and II were divided into 4 subgroups: in Ia and IIa subgroups during preparation for surgery patients received one of the agonists of gonadotropin releasing hormone (GnRH) for 3 months. In Ib and IIb subgroups suppressive therapy was not performed prior to surgical treatment. After a myomectomy women of I and II groups received one of the GnRH agonists for the first three months, followed by the low-dose combined oral contraceptive. The choice of funds was justified on the results of an immunohistochemical study of the Ki-67 antigen expression (proliferation marker), estrogen and progesterone receptors, and cyclooxygenase-2 (COX-2). Group IIb women were additionally prescribed non-hormonal therapy with fibrinolytic (streptokinase) and proteolytic (streptodornase) enzymes, as well as herbal antiproliferative agent containing indole-3-carbinol and epigallocatechin-3-gallate.

Results of the study: an immunohistochemical study showed that in women who did not receive suppressive therapy before surgery (Ib and IIb groups) Kі-67 antigen expression in the tumor nodes was significantly increased. Almost 2 times greater was the difference between the Ki-67 antigen expressions in the LM nodes with the adenomyosis combination. GnRH agonists did not inhibit the expression of estrogen and progesterone receptors. COX-2 expression was significantly higher than in intact myometrium. In women with combined uterine pathology the number of cells with a positive immunohistochemical reaction to COX-2 was 6.4 times higher than with isolated LM. Conclusions: myomectomy surgery only partially solves the problems of reproductive health restoration in women with combined uterine pathology. The proposed long-term suppressive therapy made it possible to reduce the tumor relapses number by almost 2.6 times after surgical organ-preserving treatment and to improve reproductive function in almost every third woman.

Author Biographies

В. А. Потапов, SI “Dnipropetrovsk medical academy of the MOH of Ukraine”, Dnipro

MD, professor, head of Obstetrics and Gynecology Department

В. І. Івах, Medical center “Medicover”, Dnipro

Obstetrician gynecologist


  1. Vovk, I.B., Kondratiuk, V.K., Chubei, G.V., Zakharenko, N.F. “Treatment of genital endometriosis – from evolution to revolution (literature review).” Women’s Health 4 (2009): 40–3.
  2. Vovk, I.B., Khomynska, Z.B., Zakharenko, N.F., et al. “Characteristics of hormonal status in women with endometriosis.” Women’s Health 10.56 (2010): 162–4.
  3. Grek, L.P. “Features of systemic disorders in patients with genital endometriosis in combination with benign genital diseases and chronic pelvic pain syndrome.” Medical perspectives Vol. XXII-4 (2017): 62-7.
  4. Guriev, T.D., Sidorova, I.S., Unanyan, A.L. The combination of uterine fibroids and adenomyosis. Moscow. MIA Ltd (2012): 256 p.
  5. Damirov, M.M. Current management for patient with adenomyosis. Moscow. BINOM (2015).
  6. Zakharenko, N.F. “Clinical and anamnestic characteristics of women with different forms of endometriosis.” Pediatrics, Obstetrics and Gynecology: Scientific and Practical Journal 72.5 (2010): 97–104.
  7. Zakharenko, N.F., Kovbasii, V.P., Kovalenko, N.V. “Characteristics of psychological personality types in benign hyperproliferative diseases of the female reproductive system.” Women’s Health 2.48 (2010): 133–6.
  8. Kudinova, N.N., Frolov, M.V., Naumov, N.V., Shurshukov, Y.Y. “Medical and social characteristics of women with uterine myoma in combination with adenomyosis.” Electronic journal “Postgraduate doctor”. Available from: [ gynecology/13525], last accessed Oct 22, 2019.
  9. Patent for useful model № 54872 Ukraine.Method for postoperative rehabilitation and pregrevidas preparation after conservative myomectomy / Potapov, V.O., Medvedev, M.V., Polschikov, P.I., Stepanova, D.Y., Finkova, O.P., No. u 2010 06592; appl. 31.05.2010, pub. 25.11.2010, bull. No. 22.
  10. Patent for useful model № 85891 Ukraine. Method of treatment of hyperproliferative states of the pelvic organs / Potapov, V.O., Hryschenko, O.V., Medvedev, M.V., et al., No. u 2013 04798; appl. 15.04.2013, pub. 10.12.2013, bul. No. 23.
  11. Potapov, V.A., Мedvedev, М.V., Ivakh, V.I. “Strategies for the therapy of endometriosis disease in combination with the uterine body leiomyoma.” Journal of Obstetrics and Women's Diseases Vol. LХI special edition (2012): 26–7.
  12. Strizhakov, A.N., Davydov, A.I., Pashkov, V.M., Lebedev, V.A. Benign uterine diseases. Moscow. GEOTAR-Media (2012): 288 p.
  13. Tatarchuk, T.F., Zakharenko, N.F., Tutchenko, T.N. “New approaches to the problematic issues of treatment of genital endometriosis.” Reproductive Endocrinology 3 (2013): 36–45.
  14. Tatarchuk, T.F., Zakharenko, N.F., Manoliak, I.P., Kovbasii, V.P. “Improving medical tactics in women with endometriosis.” Reproductive Endocrinology 4.18 (2014): 24–7.
  15. Tatarchuk, T.F.., Zakharenko, N.F.., Manoliak, I.P., et al. “Features of climacteric syndrome in women with endometriosis and possible ways of its correction.” Scientific journal of the MOH of Ukraine 2 (2014): 71–8.
  16. Fadeeva, N.I., Yavorskaya, S.D., Dolina, O.V., et al. “Adenomyosis: new therapeutic options.” Medical news 5 (2017): 13–15.
  17. Adamson, G.D., Pasta, D.J. “Endometriosis fertility index: the new, validated endometriosis staging system.” Fertil Steril 94 (2010): 1609–15.
  18. Bayoglu, T.Y., Dilbaz, B., Altinbas, S.K., Dilbaz, S. “Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue.” Fertil Steril 95 (2011): 492–6.
  19. Brosens, I., Brosens, J.J., Fusi, L., et al. “Risks of adverse pregnancy outcome in endometriosis.” Fertil Steril 98 (2012): 30–5.
  20. Brown, J., Pan, A., Hart, R.J. “Gonadotrophin-releasing hormone analogues for pain associated with endometriosis.” Cochrane Database Syst Rev 12 (2010): CD008475.
  21. de Ziegler, D., Gayet, V., Aubriot, F.X., et al. “Use of oral contraceptives in women with endometriosis before assisted reproduction treatment improves outcomes.” Fertil Steril 94 (2010): 2796–9.
  22. Fagervold, B., Jenssen, M., Hummelshoj, L., Moen, M.H. “Life after a diagnosis with endometriosis – a 15 years follow-up study.” Acta Obstet Gynecol Scand 88 (2009): 914–9.
  23. Giudice, L.C. “Clinical practice: endometriosis.” N Engl J Med 362 (2010): 2389–98.
  24. Guo, S.W. “Recurrence of endometriosis and its control.” Hum Reprod Update 15 (2009): 441–61.
  25. Laschke, M.W., Menger, M.D. “Anti-angiogenetic treatment strategies for the therapy of endometriosis.” Hum Reprod Update 18 (2012): 682–702.
  26. Shakiba, K., Bena, J.F., McGill, K.M., et al. “Surgical treatment of endometriosis: a 7-year follow-up on the requirement for further surgery.” Obstet Gynecol 111 (2008): 1285–92.
  27. Stratton, P., Berkley, K.J. “Chronic pelvic pain and endometriosis: translational evidence of the relationship and implications.” Hum Reprod Update 17 (2011): 327–46.



How to Cite

Потапов, В. А., & Івах, В. І. (2019). Strategy for prevention of uterine leiomyoma recurrence in combination with adenomiosis after organ-conserving operations in reproductive aged women. REPRODUCTIVE ENDOCRINOLOGY, (49), 12–16.



Tumors and pretumoral pathology